Meet the Experts Transporter Conference Budapest 2014


Welcome


As a pioneer in the drug transporter field for 15 years, SOLVO is dedicated to exploring the science of transporters and their role in xenobiotic efficacy and safety. With frequent Webinars hosted by respected scholars and professionals, as well as numerous peer-reviewed publications, our commitment and scientific contribution to the transporter field is well recognized.

With the first event in SOLVO’s Meet the Experts series, Meet the Experts: Transporter Conference – 2014, we took our commitment to the transporter field to a new level. The sessions were focusing on the most relevant and up-to-date aspects of transporter science and industry applications

Programme

2 April, 2014: Laboratory Training on Key Transporter Assays

3-4 April: “Meet the Experts: Transporter Conference – 2014”

With keynote speeches and lectures presented by prominent scientists and thought leaders in the field, this event was one of the most important, and most exciting new transporter focused events of the year.

The event took place in the historic city of Budapest, where the sights match the science, and conference breaks spent exploring the city will be as remarkable as the daytime scientific sessions.

Click here for the full agenda

Click here to access the presentations of the conference.

Day 1
Session Speaker
Welcome Krajcsi, SOLVO, Hungary
Keynote Balázs Sarkadi, Hungarian Academy of Sciences
Physiological barriers of pharmacological significance Tetsuya Terasaki, Tohoku University, Japan
Anna-Lena Ungell, UCB Pharma, Belgium
Jasminder Sahi, GSK R&D, China
Colin Brown, Newcastle University, UK
Significance of transporters in pathology and toxicology Stephan Vavricka, Zürich, Switzerland
William Ward Johnson, Consultant, USA
Roos Masereeuw, Radboud University, Netherlands
Vendor talk Maria Barthmes, Nanion, Germany
Closing remarks Péter Krajcsi, SOLVO, Hungary
Day2
Methods and models to study membrane transporters Maarten Huisman, Janssen, Belgium
Nico Scheer, Taconic Artemis, Germany
Oliver Langer, Biomedical Systems, Austria
Transporters as drug targets Birger Brodin, University of Copenhagen, Denmark
Gergely Szakács, Hungarian Academy of Sciences
Marçal Pastor-Anglada, University of Barcelona, Spain
Present practice and future applications Imad Hanna, Novartis IBR, USA
Jackie C Bloomer, GSK, UK
John Keogh, JPK Consulting, United Kingdom
Closing Remarks Péter Krajcsi, SOLVO, Hungary

Sponsors and Exhibitors:

nanion qualyst xbl


Speakers


The following speakers will be presenting at the conference.

BLOOMER, Jackie C.

BLOOMER, Jackie C.

Director, Drug Metabolism and Pharmacokinetics, GlaxoSmithKline R&D, Ware, UK

Biography

Jackie Bloomer has over 25 yrs experience in preclinical Drug Metabolism and Pharmacokinetics (DMPK) with expertise in enzyme methodologies, extrapolation of in vitro data and application of physiologically based pharmacokinetic models. She has implemented in vitro methodologies and strategies in both drug discovery and development environments to assess the risk of clinical drug-drug interactions. She has represented DMPK on drug development project teams from a variety of therapeutic areas and has been responsible for the strategic implementation of scientific initiatives in preclinical DMPK, including the application of modelling and simulation approaches. Jackie is currently a Director in DMPK at GSK leading a team responsible for the mechanistic understanding of drug absorption, distribution, metabolism and excretion and the extrapolation of this knowledge to characterise drug disposition and drug interaction risks. Her team apply a wide range of in vitro tools to understand the drug metabolising enzymes and drug transporters involved in the elimination of GSK drugs. In vitro-in vivo extrapolation techniques are used to make an assessment of mechanistic drug-drug interaction risks and dynamic modelling approaches are deployed for quantitative predictions. She is co-chair of the Drug Interaction Advisory Committee within GSK which has the remit of advising project teams on clinical drug interaction issues.
BRODIN, Birger, PhD

BRODIN, Birger, PhD

Group Leader, Associate Professor, Drug Transporters in ADME, Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Biography

Birger Brodin heads the research group "Drug Transporters in ADME" and the Cell Culture Core Facility at the Department of Pharmacy, University of Copenhagen, Denmark. The focus of the research group is the study of membrane transporters and their role in uptake and excretion of drugs and prodrugs across barrier tissues. Birger Brodin is currently investigating how drugs and endogenous substrates pass the small intestine and the blood-brain barrier, and how transport proteins affect this process. Birger Brodin is the author of > 70 scientific articles and book chapters, and several popular science articles, has given > 25 invited talks and is ad hoc referee at > 15 scientific journals.
BROWN Colin, PhD

BROWN Colin, PhD

Associate Professor Institute for Cell & Molecular Biosciences, Medical School, Newcastle University Newcastle, UK

Biography

Dr. Brown is an Associate Professor in the Institute of Cell & Molecular Biosciences, Medical School, Newcastle, UK. He received his Bachelor and Ph.D degrees in Physiology and Pharmacology from the University of St Andrews, Scotland., He then held a Royal Society European Postdoctoral Fellowship, focusing on renal phosphate transport, at the Institute of Physiology, University of Zurich, Switzerland. After this he was awarded a prestigious Wellcome Trust Senior Research Fellowship in Biomedical Sciences which he held at the School of Medicine, University of Manchester UK. After a period in Manchester, he obtained tenure at the University of Newcastle as an Associate Professor. His research interests have centered around the study of the interaction of drug molecules with transport proteins in renal, hepatic and gastrointestinal epithelia. Most recently he has developed a series of novel proximal tubule cell models with which to investigate the handling of drug molecules. He holds consultancy positions with a number of Pharmaceutical companies.
GRINDSTAFF, Kent, PhD

GRINDSTAFF, Kent, PhD

Vice Presindent, Business Development and Operations - USA, SOLVO Biotechnology, USA

Biography

Mr. Grindstaff will act as the chairman of the 2nd Day of the conference. With more than 12 years experience in early-stage drug development and transporter biology at Biopharmaceutical and Contract Research organizations, Dr. Grindstaff manages SOLVO’s operations in the Untied States and Canada since June 2012. Prior to joining SOLVO USA, he was head of research at Optivia Biotechnology, a transporter focused CRO and Biotechnology company based in Menlo Park, CA, USA. From 2000 to 2010, he held numerous scientific positions, most recently as Principal Investigator, at XenoPort Inc., Santa Clara, CA, USA. Dr. Grindstaff has a Ph.D. in Molecular Cell Biology and Biochemistry from Washington University, Saint Louis, MO, USA and completed a Senior Post-doctoral Fellowship in the Department of Molecular and Cellular Physiology at Stanford University, Palo Alto, CA, USA. He has authored numerous peer-reviewed publications, reviews, and grant applications related to epithelial barrier models and transporters.
HANNA, Imad, PhD

HANNA, Imad, PhD

Senior Fellow Novartis Institutes for BioMedical Research East Hanover, NJ USA

Biography

Dr. Imad Hanna is a Group leader in the Department of Drug Metabolism and Pharmacokinetics at Novartis Institutes for BioMedical Research in East Hanover, NJ. Dr. Hanna obtained his B.S. degree in Biochemistry from Oakland University in Rochester, MI. and his Ph.D. in Pharmacology from Wayne State University in Detroit, MI. Following a two-year postdoctoral fellowship at the Center in Molecular Toxicology at Vanderbilt University, Imad joined the Pharmaceutical industry in 2000. Currently, Imad’s group provides drug metabolism and transport support for the registration of clinical drug candidates. Imad is a member of a global team defining scientific/business strategies to assess potential drug interactions with respect to drug transporters. In this regard, he and his colleagues have implemented a number of cell-based drug transport assays in support of this strategy, as well as providing support to ongoing key projects.
HUISMAN, Maarten, PhD

HUISMAN, Maarten, PhD

Principal Scientist, Janssen, Pharmaceutical Companies of Johnson and Johnson, Antwerp Area, Belgium

Biography

Maarten was driven by ‘doing something useful for patients’ and studied Biology at the U Groningen, and obtained his PhD in 2003 at the Netherlands Cancer Institute focusing mainly on the role of multidrug transporters on the (pre)clinical pharmacokinetics of multidrug transporters. He then worked as a post-doc in a small biotech company, HepArt (academic spin-off), aiming to develop a bio-artificial liver. In 2006 he joined Janssen Pharmaceutica in Belgium (Johnson & Johnson) as a study director of pre-clinical DMPK studies. In 2007 he became team leader of the In vitro DMPK lab team and the In vivo DMPK lab team (2010). From 2007 to December 2011 he led the Center of Expertise on Drug Transporters within J&J. Since January 2012 he was accepted in an internal 2-year program, called Bridges, to also gain experience in drug discovery and to keep bridging the Discovery and Development parts of the organization. In 2014, he continued in a role in Discovery Sciences.
JANSEN, Gerrit, PhD

JANSEN, Gerrit, PhD

Department of Rheumatology Amsterdam Rheumatology and Immunology Center (ARC) Amsterdam, The Netherlands

Biography

Dr. Gerrit Jansen obtained his PhD degree in Biochemstry at the State University of Utrecht, The Netherlands in 1984. From 1985-1990 he held a post-doctoral position at the Utrecht University Medical Center (Dept. of Oncology). In 1991 he moved to the VU University Medical Center in Amsterdam (Dept. of Medical Oncology). From 1992-1994 he was a recipients of a fellowship of the Royal Netherlands Academy of Arts and Sciences, which was followed by a senior postdoctoral position at the VU University Medical Center (Dept. of Medical Oncology). In 2001 he moved to the Department of Rheumatology (currently Amsterdam Rheumatology and immunology Center) at the VU University Medical Center to become head of the laboratory for experimental rheumatology. Dr. Jansen’s main research interest focuses on molecular mechanisms of drug resistance, with a special interest for resistance mechanisms to classical (e.g. antifolates) and experimental drugs from an anti-inflammatory and anti-cancer perspective.
JOHNSON, William W., Ph.D

JOHNSON, William W., Ph.D

Consultant, Budapest, Hungary

Biography

Dr. William W. Johnson earned his Ph.D. degree in Biochemistry at the University of Maryland, USA, in 1994. He held a postdoctoral position at Vanderbilt University, USA, from 1994-1997 (INRSA, NIH, with F.P. Guengerich). He worked as a principal scientist at the Schering-Plough Research Institute, Lafayette, NJ, USA, from 1997-2003, which was followed by the position of Associate Director at OSI Pharmaceuticals, Inc., Boulder, CO, USA. In 2010 he continued his career as an Associate Director at GlaxoSmithKline, Research Triangle Park, NC, USA. He joined SOLVO Hungary in 2012 as Vice President, Director of Global Operations. Dr. Johnson’s main research interest concentrates on transporters, DM/PK, hepatotoxicity, bioactivation, metabolism, and drug interaction.
KEOGH, John, MSB, CBiol

KEOGH, John, MSB, CBiol

Independent DMPK Consultant, JPK Consulting , Hitchin, Hertfordshire, United Kingdom

Biography

John Keogh (MSB, CBiol; jpkeogh@virginmedia.com) is an independent DMPK consultant with JPK Consulting. His client base includes UCB Chiesi and Astellas. He has over 25 years drug development experience with Glaxo SmithKline (GSK), and whilst here was a key player in the development and application of transporter science expertise to facilitate drug discovery and development. He is an industry expert in membrane transporter science and strategies, is experienced in interpreting and contextualizing DMPK data to solve issues and challenges in drug development, and in refining strategies in this emerging scientific discipline. He has a wealth of specialist expertise in the evaluation of drug-drug interaction challenges, notably in the drug transporter field. John’s client services include training, practical advice on assay development and interpretation, and assistance in regulatory document preparation. John is a champion for excellence and education in the transporter field, publishing and lecturing regularly. He is an active member of a team currently working on a comprehensive volume of transporter sciences for publication in the RSC Drug Discovery Series in 2015.
KRAJCSI Péter, PhD

KRAJCSI Péter, PhD

Chief Scientific Officer, SOLVO Biotechnology Budaors, Hungary

Biography

Dr. Peter Krajcsi has extensive experience in biotechnology. He received his PhD in biochemistry from University of Szeged and later a Doctor of Sciences degree in biological sciences from the Hungarian Academy of Sciences. In his academic career he has focused on three major topics (i) steroid receptors (ii) molecular biology of adenoviruses and (iii) apoptosis. For the past 13 years he has been working in R&D management positions for small and medium size enterprises in drug research and gene therapy in Hungary as well as in the United States. Since 2002 he is the Chief Scientific Officer of Solvo Biotechnology. At Solvo the focus is on membrane transporters and utilization of membrane transporter technology in drug discovery and development as well as in development of diagnostics tools for cancer and inflammatory diseases.

LANGER, Oliver, PhD

LANGER, Oliver, PhD

Senior Scientist Health & Environment Department Biomedical Systems , AIT Austrian Institute of Technology GmbH Seibersdorf, Austria

Biography

Oliver Langer was born in 1971 in Vienna, Austria. He studied pharmacy at the University of Vienna and graduated with a Master’s degree in 1995. He obtained his PhD degree at the Karolinska Institute in Stockholm, Sweden in 2000, where he specialized in the development of radiotracers for the imaging of neurotransmitter systems with positron emission tomography (PET). During his PhD studies he spent 3 years as a research fellow at the Service Hospitalier Frédéric Joliot (French Atomic Energy Commission, CEA) in Orsay, France. Since 2002 he has been employed at the Department of Clinical Pharmacology at the Medical University of Vienna (Austria), where he became Associate Professor (“Privatdozent”) in Radiopharmaceutical Chemistry in 2006. In 2010, he became Senior Scientist at Austrian Institute of Technology in Seibersdorf, which is Austria’s largest non-university research organization. In his research, he uses preclinical and clinical PET to address different questions related to drug disposition and pharmacodynamics.
MASEREEUW, Rosalinde, PhD

MASEREEUW, Rosalinde, PhD

Professor of Experimental Pharmacology at Utrecht Institute for Pharmaceutical Sciences in The Netherlands

Biography

Roos Masereeuw (UU) received her PhD from Radboud University in Nijmegen in January 1997. This PhD program and a postdoc period were partly performed at National Institute for Environmental Sciences (NIEHS/NIH), Research Triangle Park, NC, USA. Dr. Masereeuw also visited the NIEHS/NIH institute Mount Desert Island Biological Laboratory (ME, USA) as principal investigator in 1997, 1998, 2010 and 2014. In November 1996, she joined the Dept. of Pharmacology and Toxicology at Radboudumc as assistant professor and in July 2002, she was appointed as associate professor after obtaining an NWO-ASPASIA award. In 2009, she received the Dutch Pharmacological Society (NVF) Schering-Plough Pharmacology Award, in 2010 the Galenus Research prize and in 2015 she was elected Fellow of the American Association of Pharmaceutical Scientists. She is currently president of the Dutch Pharmacological Society. Since July 2015 she is also full professor of Experimental Pharmacology at Utrecht Institute for Pharmaceutical Sciences in The Netherlands. Research in the Masereeuw group is focused on developing novel therapeutic strategies to improve kidney function in renal disorders. Her group has developed unique human renal cell lines with a high predictive value for drug transport and metabolism. These cell lines are being used in the development of a bioartificial kidney, organotypic cultures for in vitro toxicity testing of chemical entities and drugs in development, and for studying the renal tubular secretion and reabsorption machinery. Roos Masereeuw has (co-)authored over 150 scientific papers, successfully supervised 17 PhD students and currently supervises 10 PhD students and 5 post-docs

PASTOR-ANGLADA, Marçal, PhD

PASTOR-ANGLADA, Marçal, PhD

Professor of Biochemistry and Molecular Biology, Molecular Pharmacology and Experimental Therapeutics, Department of Biochemistry and Molecular Biology, University of Barcelona, Barcelona, Spain

Biography

Marçal Pastor-Anglada is a Professor of Biochemistry and Molecular Biology at the Department of Biochemistry and Molecular Biology at the University of Barcelona (UB). He is also the PI of the Molecular Pharmacology and Experimental Therapeutics group within the Oncology Program of the National Biomedical Research Institute of Liver and Gastrointestinal Diseases (CIBER EHD). He has hold positions as an INSERM researcher at the CNRS Centre de Recherches sur l’Endocrinologie Moléculaire et le Developpement and as a Research Associate at the Department of Cellular, Molecular and Developmental Biology at the University of California Santa Barbara. He has been Visiting Associate Professor at the McArdle Laboratory for Cancer Research, Department of Oncology, University of Wisconsin-Madison School of Medicine and Visiting Professor at the Cellular and Molecular Physiology Laboratory at the Pontificia Universidad Católica de Chile. He is the author of more than 150 indexed articles, mostly devoted to the study of membrane transporters. His current interests deal with the pharmacogenetics and pharmacogenomics associated with nucleoside-derived drug based therapies. His laboratory also studies the biology and pharmacology of nucleoside transporter (NT) proteins, with a particular focus on the SLC28 gene family encoding CNT plasma membrane drug carriers. Besides the analysis of their pharmacological profiles, work on the regulatory properties of these genes/proteins is a major issue in the laboratory. Overall all his projects show a great emphasis on translational research.
SAHI, Jasminder, PhD

SAHI, Jasminder, PhD

Director and Head of the Drug Metabolism and Pharmacokinetics group, GlaxoSmithKline Shanghai, China

Biography

Jasminder Sahi is Director and Head of the Drug Metabolism and Pharmacokinetics group at GlaxoSmithKline Shanghai, China and is focused on developing novel drugs for CNS indications. She received her Doctoral degree from Panjab University, India in work involving hepatotoxicity. Subsequently, she participated in a postdoctoral program at the University of Illinois at Chicago, studying membrane transport in primary human cells. Dr Sahi worked at the Department of Pharmacokinetics and Metabolism Department, at Pfizer Global Research and Development/Parke Davis, USA for 10 years, where she lead an ADME R&D group responsible for developing novel drug transporter tools. Her research focused on drug metabolism and establishing in vitro models for studying induction of drug metabolizing enzymes in human primary hepatocytes as well as hepatobiliary and renal xenobiotic transporters. Subsequently, she continued her research on induction and drug transporters as Vice President of Research and Development at CellzDirect and a Research Fellow at Invitrogen, USA. Dr Sahi is a reviewer for seven journals and on the board of two. She is a member of the organizing committee for the Land O’ Lakes DMPK conference and the Asia-Pacific CSSX conference and a sub-editor for the Encyclopedia of Metabolism and Drug Interactions. Her research contributions include over 40 peer-reviewed research articles, book chapters and invited reviews.
SARKADI Balazs, PhD, MD

SARKADI Balazs, PhD, MD

Head of Research Group Hungarian Academy of Sciences, Budapest, Hungary

Biography

Balázs Sarkadi obtained his MD degree at Semmelweis Medical University, Budapest, in 1972, and his Ph.D. in 1980. He spent several years as a post-doc and then as a visiting scientist at major universities in the United States and Canada. He is research professor at Semmelweis University, member of the Hungarian Academy of Sciences, past president of the Federation of European Biochemical Societies (FEBS), member of several international research societies including ICRO and the Academia Europeae. His research has been focusing on membrane proteins, including the investigation of ABC membrane transporters, which play a major role in the multidrug resistance of cancer, in general pharmacology, and in stem cell function. Balazs Sarkadi has published more than 220 papers in international scientific journals, with a citation number over 12,000
SCHEER, Nico, PhD

SCHEER, Nico, PhD

Director, Head of tADMET Portfolio, Taconic Artemis, Cologne, Germany

Biography

Nico Scheer: Nico, Director and Head of the tADMET™ portfolio at the German Biotech company TaconicArtemis GmbH, a subsidiary of Taconic Farms Inc., received his PhD in Developmental Biology from the University of Cologne. Within Taconic he is responsible for a portfolio of translational mouse models and services for an improved in vivo analysis of the ADMET characteristics of new compounds. As part of this responsibility he is leading a program to generate new and innovative transgenic and tissue humanized mouse lines for the PK and safety profiling of drugs. Nico has published several papers in peer-reviewed scientific journals in the field.
TERASAKI Tetsuya, PhD

TERASAKI Tetsuya, PhD

Distinguished Professor Membrane Transport and Drug Targeting Laboratory, Graduate School of Pharmaceutical Sciences, Tohoku University Sendai, Japan

Biography

Dr. Tetsuya Terasaki graduated Kanazawa University in 1977 and received Ph.D. degree from University of Tokyo in 1982. He was appointed Full Professor of Tohoku University in 1996 and the University Distinguished Professor of Tohoku University in 2008. He received the Ebert Prize from American Pharmaceutical Association in 1985, the Meritorious Manuscript Award from American Association of Pharmaceutical Scientists in 1996 and 2010, together with three Research Achievement Awards. In April 2013, he received the Medal of Honor with Purple Ribbon, bestowed by the Government of Japan to the most highly honored scientists. His major research interests are the molecular pharmacology of blood-brain barrier function and the pharmacoproteomics. He published extensively in journals, with 260 original research articles and 50 review articles and contributed chapters to over 50 books.

UNGELL, Anna-Lena, PhD

UNGELL, Anna-Lena, PhD

Director and Head of Investigative ADME UCB Pharma, Brussels Area, Belgium

Biography

Biography: Anna-Lena Ungell received her PhD degree at the University of Gothenburg, Sweden, in the area of comparative pharmacology. She has more than 25 years of experience from the Pharmaceutical Industry such as AstraZeneca in Sweden and UCB in Belgium. Anna-Lena has worked in various areas of DMPK such as drug absorption and disposition, metabolism, in vivo pharmacokinetics and models, reactive metabolites, prediction and assessments of DDI and as well as PK and PBPK modeling from early target to life cycle management. In AstraZeneca she has had managerial, scientific as well as DMPK project leader roles. Anna-Lena presently holds a position as Director and Head of Investigative ADME at UCB Pharma in Belgium. In her responsibilities lies being a manager for 25 scientists in Belgium and in UK, covering both in vitro and in vivo DMPK science delivering preclinical data in all ADME areas to projects in Neuroscience and Immunology for both chemical entities and biologicals. Anna-Lena Ungell has had numerous PhD students and Master Science students throughout her carrier and in year 2004 she received an Associate Professorship in Pharmaceutics at Uppsala University, Sweden. Anna-Lena have ca. 70 publications, both original articles and book chapters and numerous posters and oral communications
VAVRICKA, Stephan, MD

VAVRICKA, Stephan, MD

Head of the Division, Gastroenterology and Hepatology, Triemli Hospital, Zurich, Switzerland

Biography

Dr Stephan Vavricka is the Head of Gastroenterology and Hepatology, Stadtspital Triemli in Switzerland. His post doctorate positions held at University Hospital Zurich included Chief Resident and Research Fellow in Division of Gastroenterology, Resident in Division of Haematology, Internal Medicine. At University Hospital, Basel, he held the Chief Resident for Division of Gastroenterology. He also worked as a research fellow at The Martin Boyer Laboratories, University of Chicago, IBD Research Center(2002-2003) Dr Stephan Vavricka obtained awards for DDW poster of distinction in 2004, a ‘talk of distinction’ award at an investigator meeting as well as the IBD Jounior Prize of the SGGH in 2006. He works closely with the following research foundations Roche Research Foundation, Swiss National Science Foundation,Forschungskredit University of Zurich, Novartis Stiftung, Swiss National Science Foundation on projects relating to inflammatory bowel disease.

Presentations


You can access the presentations by clicking on the individual speakers, or by navigating to this page. Please note that you must be logged in to see the content.

Day 1
Title Speaker
Welcome Péter Krajcsi, SOLVO, Hungary
Keynote Balázs Sarkadi, Hungarian Academy of Sciences
Physiological barriers of pharmacological significance
Prediction of in vivo blood-brain barrier drug transport from in vitro study combined with transporter protein quantification Tetsuya Terasaki, Tohoku University, Japan
Intestinal Transporters: regional profiles, in vitro models and their clinical relevance. Anna-Lena Ungell, UCB Pharma, Belgium
Hepatic Transporters and their Role in Drug Uptake and Elimination Jasminder Sahi, GSK R&D, China
Development of in-vitro cross species renal proximal tubule DMPK and drug safety platforms Colin Brown, Newcastle University, UK
Significance of transporters in pathology and toxicology
Regulation of transporter expression in inflammatory and hypoxic conditions Stephan Vavricka, Zürich, Switzerland
Role and influence of transmembrane transporters in hepatotoxicity William Ward Johnson, Consultant, USA
Renal drug transporters in drug‐induced toxicity Roos Masereeuw, Radboud University, Netherlands
Vendor talk Maria Barthmes, Nanion, Germany
Closing remarks Péter Krajcsi, SOLVO, Hungary
Day2
Methods and models to study membrane transporters
Overview of available in vitro transporter models - advantages & challenges Maarten Huisman, Janssen, Belgium
Humanized animal models to study membrane transporters Nico Scheer, Taconic Artemis, Germany
Studying transporter‐mediated drug‐drug interactions with PET Oliver Langer, Biomedical Systems, Austria
Transporters as drug targets
Design of prodrugs targeting the intestinal di/tri‐peptide transporter hPEPT1 (SLC15A1) Birger Brodin, University of Copenhagen, Denmark
  Gergely Szakács, Hungarian Academy of Sciences
Nucleoside transporter proteins in anticancer and antiviral therapies Marçal Pastor-Anglada, University of Barcelona, Spain
Present practice and future applications
Tailor‐made transporter assays for stage‐specific drug discovery and development Imad Hanna, Novartis IBR, USA
Drug transporters and PBPK modelling–challenges and opportunities Jackie C Bloomer, GSK, UK
The impact of advances in drug transporter sciences on regulatory agency expectations John Keogh, JPK Consulting, United Kingdom
Closing Remarks Péter Krajcsi, SOLVO, Hungary